Revenue Performance:
- Total revenue for Q3 2025 stood at $72 million, a 9.2% increase from Q3 2024.
- MedTech revenue surged by 22%, accounting for 44% of total revenue, reflecting management's strategic focus on high-margin products.
Profitability:
- Gross profit amounted to $38.9 million, translating to a gross profit margin of 54%, an increase from the previous year.
- Adjusted EBITDA was $1.3 million, marking a notable turnaround from a loss of $3.6 million in Q3 2024.
- Net income reflected a loss of $4.4 million, with adjusted EPS improving to a loss of $0.08 per share from $0.16 in the prior year.
Balance Sheet Health:
- The company holds $44.8 million in cash and cash equivalents, supporting its operational endeavors.
- Total assets stand at $285.4 million, with total liabilities of $99.5 million, evidencing a solid capital structure.
- Current ratio at 2.21 indicates sound liquidity.